Beam Therapeutics (BEAM) president exercises 35,505 stock options

Rhea-AI Filing Summary

Beam Therapeutics Inc. president Giuseppe Ciaramella reported exercising stock options to acquire a total of 35,505 shares of common stock on June 17, 2026. These transactions were coded “M,” indicating exercises or conversions of derivative securities rather than open‑market purchases or sales.

The options exercised carried strike prices of $1.03 and $0.67 per share. The underlying options had vesting schedules beginning February 26, 2018, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments, reflecting long-term equity compensation.

Insider Trade Summary

35,505 shares exercised/converted

Mixed 4 txns

Insider Ciaramella Giuseppe

Role President

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	6,505	$0.00	--
Exercise	Stock Option (Right to Buy)	29,000	$0.00	--
Exercise	Common Stock	6,505	$0.67	$4K
Exercise	Common Stock	29,000	$1.03	$30K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct, null); Common Stock — 224,911 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options exercised: 35,505 shares Strike price 1: $1.03/share Strike price 2: $0.67/share +3 more

6 metrics

Options exercised 35,505 shares Total derivative shares exercised on June 17, 2026

Strike price 1 $1.03/share Exercise price for 29,000 option shares

Strike price 2 $0.67/share Exercise price for 6,505 option shares

Transaction code M Exercise or conversion of derivative security

Option expiration 1 July 13, 2028 Expiration date for $1.03 options

Option expiration 2 May 8, 2028 Expiration date for $0.67 options

Key Terms

Stock Option (Right to Buy), derivative security, vesting commencement dates, substantially equal monthly installments

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vesting commencement dates financial

""the vesting commencement dates, February 26, 2018""

substantially equal monthly installments financial

"“remaining shares vested in 36 substantially equal monthly installments”"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 04:05 PM Accepted by SEC EDGAR 06/22/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ciaramella Giuseppe

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		M		6,505	A	$0.67	224,911	D
Common Stock	06/17/2026		M		29,000	A	$1.03	253,911	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.67	06/17/2026		M			6,505	(1)	05/08/2028	Common Stock	6,505	$0	0	D
Stock Option (Right to Buy)	$1.03	06/17/2026		M			29,000	(1)	07/13/2028	Common Stock	29,000	$0	56,946	D

Explanation of Responses:

1. The shares subject to these stock options vested 25% on the first anniversary of the vesting commencement dates, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

	By: /s/ Christine Bellon, Attorney-in-fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BEAM president Giuseppe Ciaramella report?

Giuseppe Ciaramella reported exercising stock options to acquire 35,505 Beam Therapeutics common shares. The Form 4 shows option exercises, not open‑market trades, reflecting the use of previously granted equity awards as part of long-term compensation.

How many Beam Therapeutics (BEAM) shares were acquired in this Form 4?

The filing shows option exercises for 35,505 Beam Therapeutics common shares. These came from two stock option grants, delivering 29,000 shares at one strike price and 6,505 shares at another, all recorded as derivative exercises rather than market purchases.

At what prices did the BEAM options exercised by the president vest?

The options exercised carried strike prices of $1.03 and $0.67 per share. These low exercise prices reflect historic grant dates, with vesting beginning in 2018 and completing through monthly installments under the original award schedules.

Were any Beam Therapeutics (BEAM) shares sold in this insider filing?

No sales are reported; all transactions are coded “M” for derivative exercises or conversions. This indicates the president converted stock options into common shares, with no open‑market dispositions or tax-withholding share transactions shown in the reported data.

What does the vesting schedule in BEAM’s Form 4 footnote indicate?

The footnote explains that 25% of the option shares vested one year after the February 26, 2018 commencement date, with the remaining 75% vesting in 36 equal monthly installments. This describes a standard multi-year vesting structure for Beam’s equity compensation.

Do any stock options remain after the BEAM president’s exercises?

The derivative summary section is empty, indicating no remaining derivative positions are listed in this filing. That suggests the options covered here were fully exercised, although any other awards not referenced would appear in separate disclosures.